These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23257857)

  • 1. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 3. China buys US sequencing firm.
    Baker M
    Nature; 2012 Sep; 489(7417):485-6. PubMed ID: 23018943
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology. Bankruptcy won't stop deCODE, says its founder, Stefánsson.
    Kaiser J
    Science; 2009 Nov; 326(5957):1172. PubMed ID: 19965439
    [No Abstract]   [Full Text] [Related]  

  • 5. AstraZeneca launches project to sequence 2 million genomes.
    Ledford H
    Nature; 2016 Apr; 532(7600):427. PubMed ID: 27121821
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 7. Icelandic genomics firm goes bankrupt.
    Check Hayden E
    Nature; 2009 Nov; 462(7272):401. PubMed ID: 19940890
    [No Abstract]   [Full Text] [Related]  

  • 8. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 9. Swooping for biotech.
    Wadman M
    Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomics down under. A talk with John Mattick Director of the Australian Genome Research Facility, and Co-Director of the Institute for Molecular Bioscience. Interview by Holger Breithaupt.
    Mattick J
    EMBO Rep; 2000 Sep; 1(3):204-7. PubMed ID: 11256598
    [No Abstract]   [Full Text] [Related]  

  • 11. AbbVie buys last available priority voucher for $350 million.
    Morrison C
    Nat Biotechnol; 2015 Nov; 33(11):1120. PubMed ID: 26544127
    [No Abstract]   [Full Text] [Related]  

  • 12. Troubled UK biotech firm faces new probe.
    Masood E
    Nature; 1998 Apr; 392(6679):852. PubMed ID: 9582060
    [No Abstract]   [Full Text] [Related]  

  • 13. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 14. Rediscovering plant-based drugs.
    Littleton J; Falcone D; Davies HM
    Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
    [No Abstract]   [Full Text] [Related]  

  • 15. Icelandic biotech feels the pinch.
    Wadman M
    Nature; 2008 Oct; 455(7215):842. PubMed ID: 18938257
    [No Abstract]   [Full Text] [Related]  

  • 16. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotech boot camp.
    Ledford H
    Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
    [No Abstract]   [Full Text] [Related]  

  • 18. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 19. Hatteras rounds up $90 million to lead biotech rebound in North Carolina.
    Erickson D
    Nat Biotechnol; 2015 Nov; 33(11):1121-2. PubMed ID: 26544128
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.